Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis

Table 3

Comparison of pediatric and adult data.

	Serum suPAR levels (No. of studies/No. of patients)
	pFSGS	Controls	pFSGS	MCD
Pediatric	(3 studies, )	(3 studies, )	(5 studies, )	(5 studies, )
Adult	(6 studies, )	(6 studies, )	(8 studies, )	(8 studies, )

suPAR: soluble urokinase-type plasminogen activator receptor; pFSGS: primary focal segmental glomerulosclerosis; MCD: minimal change disease.